Company Analysis
Sign in

Aldeyra Therapeutics, Inc. (ALDX)

Nasdaq: ALDX · Pharmaceutical Preparations · Lexington, MA · filing with the SEC since 2005
Full chart Alerts Compare
Grade6.5
◀ Past 6.9● Present 6.1▶ Future 6.6
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

42 patents granted to the 5 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Aldeyra Therapeutics, Inc.’s names, not what it holds today.

Patents granted
42
42 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 9 in 2024 and 6 in 2023
Applications published
67
3 of them in 2025
Names they are printed under
5
its own name, a former name
By yearGrantedApplications published
'09'11'12'13'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals21
Organic fine chemistry3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name5 counted
Aldeyra Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
61 published
Aldeyra Therapeutics, Inc. its own name
US, as the owner printed on each patent
39 granted
0 published
NEURON SYSTEMS, INC. a former name
US, as the owner printed on each patent
1 granted
4 published
ALDEXA THERAPEUTICS, INC. a former name
named as the applicant on its applications, in US
0 granted
2 published
Aldexa Therapeutics, Inc. a former name
US, as the owner printed on each patent
2 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Mar 4, 202512,240,816Deuterated compounds and uses thereofPharmaceuticalsAldeyra Therapeutics, Inc.
Oct 29, 202412,128,013Toxic aldehyde related diseases and treatmentPharmaceuticalsAldeyra Therapeutics, Inc.
Sep 24, 202412,098,132Process for preparation of aldehyde scavenger and intermediatesOrganic fine chemistryAldeyra Therapeutics, Inc.
Sep 24, 202412,097,188Compositions and methods for the treatment of macular degenerationPharmaceuticalsAldeyra Therapeutics, Inc.
Aug 20, 202412,064,516Pharmaceutical formulations and uses thereofPharmaceuticalsAldeyra Therapeutics, Inc.
Jul 9, 202412,029,735Polymorphic compounds and uses thereofPharmaceuticalsAldeyra Therapeutics, Inc.
Jun 11, 202412,006,298Polymorphic compounds and uses thereofOrganic fine chemistryAldeyra Therapeutics, Inc.
Jun 11, 202412,005,061Ophthalmic formulations of methotrexatePharmaceuticalsAldeyra Therapeutics, Inc.
Jun 11, 202412,005,060Ophthalmic formulations of methotrexatePharmaceuticalsAldeyra Therapeutics, Inc.
Feb 27, 202411,911,385Methotrexate treatment methodsPharmaceuticalsAldeyra Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jul 17, 20252025/0228840METHODS OF TREATING SJÖGREN-LARSSEN SYNDROMEPharmaceuticalsAldeyra Therapeutics, Inc.
May 8, 20252025/0144080COMPOSITIONS AND METHODS FOR THE TREATMENT OF MACULAR DEGENERATIONPharmaceuticalsAldeyra Therapeutics, Inc.
Apr 24, 20252025/0127733TOXIC ALDEHYDE RELATED DISEASES AND TREATMENTPharmaceuticalsAldeyra Therapeutics, Inc.
Nov 21, 20242024/0383870HETEROCYCLIC ALDEHYDE TRAPPING COMPOUNDS AND USES THEREOFOrganic fine chemistryAldeyra Therapeutics, Inc.
Jun 20, 20242024/0197740METHOTREXATE TREATMENT METHODSPharmaceuticalsAldeyra Therapeutics, Inc.
Jun 13, 20242024/0189260TOXIC ALDEHYDE RELATED DISEASES AND TREATMENTPharmaceuticalsAldeyra Therapeutics, Inc. · patent 12,128,013 granted from it
May 30, 20242024/0174614COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASEPharmaceuticalsAldeyra Therapeutics, Inc.
May 9, 20242024/0148700COMPOSITIONS AND METHODS FOR THE TREATMENT OF MACULAR DEGENERATIONPharmaceuticalsAldeyra Therapeutics, Inc. · patent 12,097,188 granted from it
May 2, 20242024/0139173OPHTHALMIC FORMULATIONS AND USES THEREOFPharmaceuticalsAldeyra Therapeutics, Inc.
Apr 25, 20242024/0132451DEUTERATED COMPOUNDS AND USES THEREOFPharmaceuticalsAldeyra Therapeutics, Inc. · patent 12,240,816 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 9 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ALDX · research, not advice